A placebo-controlled blinded comparison of nedocromil sodium and beclomethasone dipropionate in bronchial asthma

Two hundred and two patients aged 12-78 with chiefly moderate to severe asthma took part in a multicenter randomized blined group comparison of nedocromil sodium (NS) 4 mg four times daily, beclomethasone dipropionate (BD) 0.1 mg four times daily, and placebo. Patients were assessed at the start and end of a two week baseline and after three and six weeks of treatment. Compared with placebo, both NS and BD significantly improved day-time dyspnoea and day and nighttime cough, as assessed by diary card scores. Lung function (FEV₁) was significantly improved in the BD group. In the NS group there was also a significant reduction in concomitant use of inhaled β ₂-agonists. Overall opinions of efficacy by clinicians and patients were significantly in favor of both active treatments over placebo. There were no significant differences between the three treatments for peak expiratory flow rates, morning tightness or nighttime dyspnoea. Comparison between the two active treatments showed no significant differences in any of the variables.